← Back to Search

Histone Deacetylase Inhibitor

ACY-241 combo with Ipi and Nivo for Melanoma

Phase 1
Waitlist Available
Led By Jeffrey S Weber
Research Sponsored by Celgene
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Summary

Determine the safety, tolerability, dose-limiting toxicities (DLTs), maximum tolerated dose (MTD), and recommended Phase 2 dose (RP2D) of ACY-241 in combination with ipilimumab and nivolumab in patients with unresectable Stage III/Stage IV melanoma.

Eligible Conditions
  • Melanoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

1Treatment groups
Experimental Treatment
Group I: ACY-241 combo with Ipi and NivoExperimental Treatment3 Interventions
ACY-241 in Combination with Ipilimumab and Nivolumab
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ACY-241
2016
Completed Phase 1
~30
Nivolumab
FDA approved
Ipilimumab
FDA approved

Find a Location

Who is running the clinical trial?

CelerionIndustry Sponsor
83 Previous Clinical Trials
7,865 Total Patients Enrolled
Syneos HealthOTHER
175 Previous Clinical Trials
68,398 Total Patients Enrolled
3 Trials studying Melanoma
509 Patients Enrolled for Melanoma
CelgeneLead Sponsor
645 Previous Clinical Trials
130,439 Total Patients Enrolled
10 Trials studying Melanoma
1,169 Patients Enrolled for Melanoma
~0 spots leftby Oct 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top